CRS-HIPEC Improves Survival in Malignant Peritoneal Mesothelioma
Study of 118 patients with malignant peritoneal mesothelioma revealed cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) led to longer overall and progression-free survival. The platinum-pemetrexed combination was effective for metastatic patients and those medically inoperable. Non-surgical patients had poorer prognoses. CRS-HIPEC emerged as a safe and effective treatment, offering better survival outcomes and low morbidity rates.
In patients with gastric cancer and positive peritoneal lavage cytology or localized peritoneal metastasis, upfront chemotherapy followed by surgery yields better outcomes than surgery followed by chemotherapy.
Secondary cytoreductive surgery with hyperthermic intraperitoneal chemotherapy improves survival for select patients with recurrent colorectal cancer peritoneal metastases.
